Онглиза Drug photo

The description is actual on 01.10.2015

  • Latin name: Onglyza
  • ATH code: A10BH03
  • Active ingredient: Saksagliptin (Saxagliptin)
  • Producer: Bristol-Myers Squibb Company (USA)


As a part of this drug there is an active component saksagliptin (a hydrochloride form), also additional components: MKTs, lactoses monohydrate, croscarmellose sodium, magnesium stearate, Acidum hydrochloricum of 1 M or solution of sodium of hydroxide of 1 M, dyes.

Release form

This medicine is issued in the form of tablets with a film cover.

  • Tablets of 2,5 mg: color of a cover yellow, tablets biconvex, round, on the one hand a text "2.5", on the other hand — "4214". Texts are put in the blue color. Tablets are packed into blisters from a foil, in cardboard packs – on 3 blisters.
  • Tablets of 5 mg: color of a cover pink, tablets biconvex, round, on the one hand a text "5", on the other hand — "4215". Texts are put in the blue color. Tablets are packed into blisters from a foil, in cardboard packs – on 3 blisters.

Pharmacological action

Ongliz's drug in structure has active agent saksagliptin which is very strong selection competitive reversible inhibitor dipeptidilpeptidazy-4.

If drug is accepted by patients who are ill a diabetes mellitus, at them for 24 hours activity of DPP-4 enzyme is suppressed.

After the patient accepted glucose inside, owing to inhibition of DPP-4 occurs to the 2-3-fold growth of concentration of glyukozozavisimy insulinotropny polypeptide, glyukagonopodobny peptide-1. Concentration of a glucagon and strengthening of response glyukozozavisimy reaction of beta cells decreases. As a result in an organism concentration of insulin and S-peptide increases.

Thanks to insulin release lowering of a glycemia on an empty stomach, reduction of a postprandialny glycemia comes beta cells of a pancreas and to reduction of release of a glucagon from pancreatic alpha cells.

In the course of reception of a saksagliptin at patients increase in weight is not observed.

Pharmacokinetics and pharmacodynamics

In an organism saksagliptin it is soaked up quickly after reception to food. After oral administration about 75% of a dose are soaked up. saksagliptin and its metabolite contact blood proteins slightly.

The maximum concentration of a saksagliptin and its main metabolite is noted in plasma respectively for 2 hours and 4 hours.

On average, duration of final semi-removal and its metabolite is equal respectively 2.5 hours and 3.1 hours. It is removed with bile and with urine.

Indications to use

Ongliz's medicine is shown to use at a diabetes mellitus of the second type as an additional tool to physical activity and dietary food for the purpose of improvement of glycemic control. It can be appointed in the following quality:

  • for the purpose of monotreatment;
  • for the starting combined treatment with the drug Metforminum;
  • as addition to monotreatment of a tiazolidindionama, Metforminum, sulfonilomochevina derivatives if there is no adequate glycemic control on such treatment.


Ongliza's use in such cases is contraindicated:

  • the patient with a diabetes mellitus of the first type;
  • use of medicine together with insulin reception;
  • lactose intolerance, intolerance of a galactose, glyukozo-galaktozny malabsorption inborn;
  • diabetic ketoacidosis;
  • pregnancy and feeding by a breast;
  • the increased sensitivity to any of drug components.

Carefully appoint medicine to the people having a moderate and heavy renal failure, to elderly patients, and also those who accepts derivative sulfonilmochevina.

Side effects

The following side effects in the course of administration of drug of Ongliz are shown:

  • infections of urinary tract and upper respiratory tracts;
  • sinusitis;
  • gastroenteritis;
  • vomiting;
  • headaches.

Against the combined treatment with Metforminum the nasopharyngitis, headaches can be shown.

Ongliza, application instruction (Way and dosage)

It is necessary to accept means orally, irrespective of the period of reception of food.

If to the patient monotreatment is appointed, he is recommended to take a pill at the rate of 5 mg of a saksagliptin once a day.

If the combined treatment is appointed, it is necessary to accept 5 mg of a saksagliptin once a day, combining reception with tiazolidindiona and Metforminum, with drugs derivative sulfonilmochevina.

At the beginning of the combined treatment with Metforminum the dose of a saksagliptin is equal to 5 mg, and Metforminum dose — 500 mg a day.

If the patient missed Ongliza's reception, it is necessary to take a pill at once as soon as the person remembers it. The double dose should not be drunk.

Patients with easy degree of a renal failure can not adjust a dose. To patients with a heavy or moderate renal failure, and also those who is on a hemodialysis it is necessary to accept 2.5 mg of medicine a day. It is necessary to drink tablets after a hemodialysis.

If the patient at the same time applies strong CYP 3A4/5 inhibitors, Ongliza's dose has to make 2.5 mg a day.


There is no description of symptoms of intoxication at long reception of high doses of means. At overdose practice a symptomatic treatment. Active agent and its metabolite can be removed from an organism by means of a hemodialysis.


It agrees with data of researches, there is rather small risk of interaction of a saksagliptin significant clinically with other drugs.

At simultaneous use with inductors of isoenzymes of CYP 3A4/5 (Dexamethasone, Carbamazepine, Phenobarbital, Rifampicin, Phenytoinum) concentration of the main metabolite of a saksagliptin can decrease.

As derivative sulfonilmochevina can provoke manifestation of a hypoglycemia to reduce risk, perhaps, the dose decline of drugs sulfonilmochevina derivatives is required at a concomitant use with Ongliza.

Terms of sale

Ongliza according to the recipe is on sale.

Storage conditions

It is necessary to protect Ongliza from children, at this t there should not be above 30 °C.

Period of validity

It is possible to store Ongliz's tablets 3 years.

Special instructions

It is necessary to consider that use of medicine of Ongliz together with insulin and as a part of triple treatment (Metforminum, tiazolidindiona, derivative sulfonilmochevina) at the moment was not studied.

Researches concerning impact of drug on ability to driving of transport and work with exact mechanisms were not conducted. Nevertheless, it is necessary to consider that after administration of drug dizziness can be shown.

Ongliza's analogs

Coincidence on the ATH code of the 4th level:

Ongliza's analogs on active ingredient are absent. Similar impact on an organism is made by means Nesina, Yanuviya, Galvus, Trazhenta, Kombogliza XR. Categorically it is impossible to take this medicine without appointment of the doctor.


  • Ongliza of 5 mg No. 30 tabletkibristol Myers Skvibb

Drugstore of IFC

  • Ongliza tbl p / about 5 mg No. 30 *, Bristol-Myers Squibbssha
  • Ongliza tbl p / about 5 mg No. 30, Bristol-Myers Squibbssha
to show still


  • Ongliza of a tablet 2.5mg No. 30astrazeneka (Great Britain)
  • Ongliza30


  • Ongliza of the tab. 2.5mg Myers Skvibb's No. 30 Bristol
  • Ongliza of the tab. 2.5mg Myers Skvibb's No. 30 Bristol


  • Ongliza of 5 mg No. 30 tabl.p.p.o. Bristol-Mayerrs Skvibb of Menyufekchuring Company (USA)
to show still
Section: Diabetic
in more detail

Education: "Pharmacy" graduated from the Rovno state basic medical college majoring in. Graduated from the Vinnytsia state medical university of M. I. Pirogov and internship on its base.

Experience: From 2003 to 2013 – worked at positions of the pharmacist and manager of a pharmaceutical booth. It is awarded by diplomas and distinctions for long-term and honest work. Articles on medical subject were published in local editions (newspaper) and on various Internet portals.

PAY ATTENTION! Information on drugs on the website is help generalizing, collected from public sources and can form the basis for making decision on use of medicines it is not aware of treatment. Before medicine use of Ongliz surely consult with the attending physician.